JP2015512883A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512883A5
JP2015512883A5 JP2014560060A JP2014560060A JP2015512883A5 JP 2015512883 A5 JP2015512883 A5 JP 2015512883A5 JP 2014560060 A JP2014560060 A JP 2014560060A JP 2014560060 A JP2014560060 A JP 2014560060A JP 2015512883 A5 JP2015512883 A5 JP 2015512883A5
Authority
JP
Japan
Prior art keywords
group
carbon atoms
alkyl
pharmaceutically acceptable
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014560060A
Other languages
English (en)
Japanese (ja)
Other versions
JP6378630B2 (ja
JP2015512883A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/028438 external-priority patent/WO2013130892A1/en
Publication of JP2015512883A publication Critical patent/JP2015512883A/ja
Publication of JP2015512883A5 publication Critical patent/JP2015512883A5/ja
Application granted granted Critical
Publication of JP6378630B2 publication Critical patent/JP6378630B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014560060A 2012-03-02 2013-02-28 皮膚の疾患、障害、および異常の治療のための肝臓x受容体(lxr)調節因子 Expired - Fee Related JP6378630B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606160P 2012-03-02 2012-03-02
US61/606,160 2012-03-02
PCT/US2013/028438 WO2013130892A1 (en) 2012-03-02 2013-02-28 Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018145589A Division JP6800922B2 (ja) 2012-03-02 2018-08-02 皮膚の疾患、障害、および異常の治療のための肝臓x受容体(lxr)調節因子

Publications (3)

Publication Number Publication Date
JP2015512883A JP2015512883A (ja) 2015-04-30
JP2015512883A5 true JP2015512883A5 (enExample) 2016-04-28
JP6378630B2 JP6378630B2 (ja) 2018-08-22

Family

ID=49083313

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014560060A Expired - Fee Related JP6378630B2 (ja) 2012-03-02 2013-02-28 皮膚の疾患、障害、および異常の治療のための肝臓x受容体(lxr)調節因子
JP2018145589A Expired - Fee Related JP6800922B2 (ja) 2012-03-02 2018-08-02 皮膚の疾患、障害、および異常の治療のための肝臓x受容体(lxr)調節因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018145589A Expired - Fee Related JP6800922B2 (ja) 2012-03-02 2018-08-02 皮膚の疾患、障害、および異常の治療のための肝臓x受容体(lxr)調節因子

Country Status (25)

Country Link
US (5) US8987318B2 (enExample)
EP (2) EP2820013B9 (enExample)
JP (2) JP6378630B2 (enExample)
KR (1) KR102112879B1 (enExample)
CN (1) CN104284893B (enExample)
AU (1) AU2013225840B2 (enExample)
BR (1) BR112014021515A2 (enExample)
CA (1) CA2866113C (enExample)
CY (1) CY1120742T1 (enExample)
DK (1) DK2820013T3 (enExample)
ES (1) ES2691079T3 (enExample)
HR (1) HRP20181623T1 (enExample)
HU (1) HUE040231T2 (enExample)
IL (1) IL234413B (enExample)
LT (1) LT2820013T (enExample)
MX (1) MX361349B (enExample)
NZ (1) NZ629636A (enExample)
PL (1) PL2820013T3 (enExample)
PT (1) PT2820013T (enExample)
RS (1) RS57863B9 (enExample)
SG (2) SG10201607345YA (enExample)
SI (1) SI2820013T1 (enExample)
SM (1) SMT201800630T1 (enExample)
TR (1) TR201815013T4 (enExample)
WO (1) WO2013130892A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2691079T3 (es) 2012-03-02 2018-11-23 Ralexar Therapeutics, Inc. Moduladores del receptor X hepático (LXR) para el tratamiento de enfermedades, trastornos y afecciones dérmicas
ES2694001T3 (es) * 2013-03-15 2018-12-17 Bristol-Myers Squibb Company Moduladores de LXR
CN104151300B (zh) * 2013-05-15 2018-07-13 中国医学科学院医药生物技术研究所 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途
WO2015035027A1 (en) * 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators
ES2804304T3 (es) 2013-09-04 2021-02-05 Ellora Therapeutics Inc Moduladores del receptor X hepático (LXR)
CA2939120A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
EP3397258A2 (en) 2015-12-30 2018-11-07 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (CONICET) Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
WO2021009664A1 (en) 2019-07-15 2021-01-21 Novartis Ag Methods for treating meibomian gland dysfunction with liver x receptor agonists
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ,インコーポレーテッド 金属塩及びその使用
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1199771A (en) * 1915-07-01 1916-10-03 Bates Valve Bag Co Wire-twisting machine.
ATE283253T1 (de) 2000-09-18 2004-12-15 Glaxo Group Ltd Substituierte aminopropoxyarylderivate als lxr agonisten
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2003241601A1 (en) 2002-05-24 2003-12-12 Pharmacia Corporation Anilino liver x-receptor modulators
AU2003233670A1 (en) 2002-05-24 2003-12-12 Pharmacia Corporation Sulfone liver x-receptor modulators
ATE496893T1 (de) 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc Isochinolinonderivate und deren verwendung als medikamente
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−4(3h)−オン化合物
WO2005113499A1 (ja) 2004-05-20 2005-12-01 Sankyo Company, Limited インドール化合物
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
US7592363B2 (en) 2004-08-03 2009-09-22 Wyeth Indazoles
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
US7213797B2 (en) 2005-05-20 2007-05-08 Garland Jerome Gaskins Deck board straightener
CN101248048B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 吡唑基lxr调节剂
JP5237799B2 (ja) 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのlxrモジュレーター
WO2007031791A1 (en) 2005-09-16 2007-03-22 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
CA2627900A1 (en) 2005-11-14 2007-08-16 Irm Llc Compounds and compositions as lxr modulators
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
US8338437B2 (en) * 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
MX2009012474A (es) 2007-05-18 2009-12-18 Wyeth Corp Compuestos de quinazolina.
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
CA2695088C (en) 2007-08-13 2013-03-12 F. Hoffmann-La Roche Ag Novel piperazine amide derivatives
JP2011507905A (ja) 2007-12-21 2011-03-10 ワイス・エルエルシー ベンズイミダゾール化合物
US20110112135A1 (en) 2007-12-21 2011-05-12 Singhaus Jr Robert Ray Imidazo [1,2-A] Pyridine Compounds
US20120015988A1 (en) * 2008-05-13 2012-01-19 Boehringer Ingelheim International Gmbh Sulfone Compounds Which Modulate The CB2 Receptor
US8063088B2 (en) 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
EP2352725A1 (en) 2008-11-07 2011-08-10 Wyeth LLC Quinoxaline-based lxr modulators
CA2742023A1 (en) 2008-11-19 2010-05-27 Wyeth Llc Polar quinazolines as liver x receptors ( lxrs ) modulators
JP2012513399A (ja) 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
US20120058133A1 (en) * 2009-02-19 2012-03-08 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
EP2398474A4 (en) 2009-02-23 2012-12-05 Presidio Pharmaceuticals Inc HCV NS5A SHEMMER
CA2761934C (en) 2009-05-28 2018-01-09 Exelixis Patent Company Llc Substituted 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole compounds and their use as lxr modulators
WO2011045415A2 (en) 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
WO2012020820A1 (ja) * 2010-08-11 2012-02-16 大正製薬株式会社 ヘテロアリール-ピラゾール誘導体
AU2011293201B2 (en) * 2010-08-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
ES2691079T3 (es) 2012-03-02 2018-11-23 Ralexar Therapeutics, Inc. Moduladores del receptor X hepático (LXR) para el tratamiento de enfermedades, trastornos y afecciones dérmicas
CA2882292C (en) 2012-08-13 2023-10-17 The Rockefeller University Treatment and diagnosis of melanoma
WO2015035027A1 (en) 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators
ES2804304T3 (es) 2013-09-04 2021-02-05 Ellora Therapeutics Inc Moduladores del receptor X hepático (LXR)

Similar Documents

Publication Publication Date Title
JP2015512883A5 (enExample)
JP2015042636A5 (ja) 有機化合物
JP2014526533A5 (enExample)
JP2015522045A5 (enExample)
JP2016503797A5 (enExample)
JP2013542218A5 (enExample)
JP2014508753A5 (enExample)
JP2019514874A5 (enExample)
JP2015520140A5 (enExample)
JP2017526674A5 (enExample)
JP2015199738A5 (enExample)
JP2016503793A5 (enExample)
JP2017536416A5 (enExample)
JP2016505614A5 (enExample)
MY187617A (en) Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof
JP2014513036A5 (enExample)
JP2013010731A5 (ja) 複素環化合物
BR112016025356A2 (pt) 4-fenilpiperidinas substituido, sua preparação e utilização
JP2013532130A5 (enExample)
JP2017524067A5 (enExample)
JP2011227454A5 (enExample)
JP2015063518A5 (ja) 有機化合物
JP2015518492A5 (enExample)
JP2017538769A5 (enExample)
JP2011016798A5 (enExample)